Trial Profile
A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients With Essential Hypertension and Type 2 Diabetes in Asia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Azilsartan medoxomil (Primary)
- Indications Essential hypertension; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 26 Jan 2017 Status changed from recruiting to completed.
- 28 Jul 2016 Planned patient no changed from 494 to 363.
- 20 Jul 2016 Planned End Date changed from 1 May 2016 to 1 Dec 2016.